Systemic Inflammatory Markers for Prediction of Bevacizumab Benefit in Glioblastoma Multiforme.

Creative Commons License

Besiroglu M., Shbair A. T., Yasin A. I., Topcu A., Turk H. M., Demir T.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, vol.31, pp.39-44, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 31
  • Publication Date: 2021
  • Doi Number: 10.29271/jcpsp.2021.01.39
  • Journal Name: Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.39-44
  • Keywords: C-reactive protein-to-albumin ratio (AR), Glioblastoma multiforme, Neutrophil-to-lymphocyteratio (NLR), Platelet-to-lymphocyte ratio (PLR), Predictive score, RESECTION
  • Bezmialem Vakıf University Affiliated: Yes


Objective: To evaluate the predictive significance of systemic inflammation markers (SIMs) in patients with glioblastoma multiforme (GBM), who were treated with bevacizumab (Beva).